Boston Scientific Corp. on Thursday won approval from the U.S. Federal Trade Commission for its $27 billion acquisition of Guidant Corp., on condition that the company bring a new competitor to the market by selling all assets related to Guidant’s vascular business to Abbott Laboratories. The FTC also insisted that Boston Scientific restructure its relationship with a startup company that is planning to enter the market for implantable defibrillators.
Popularity: 1% [?]
Posted on Friday, April 21st, 2006. Filed under: Business Law, Law Misc
You can leave a response, or trackback from your own site.
Rate This Post - Vote Now!